



**XIth International
Myeloma Workshop**
& **IVth International Workshop
on Waldenström's
Macroglobulinemia**

Kos Island, Greece, 25-30 June 2007

Organized by:

Department of Clinical Therapeutics

Alexandra Hospital

Medical School

National & Kapodistrian University of Athens

***IVth International
Workshop on Waldenström's
Macroglobulinemia***

Scientific Programme

*IVth International Workshop on
Waldenström's Macroglobulinemia
Scientific Programme*

Friday, June 29, 2007

Hall Hippocrates

14:00-14:30		Opening Addresses - Kyle Award
14:30-16:50	WM1	Genetics, Pathophysiology and Staging System Chair: M.A. Dimopoulos, Greece - S. Treon, USA
14:30-14:50	WM1.1	G.A. Pangalis, Greece: Biologic and clinical overlap of IgM-Secreting lymphomas; Focus on Waldenström's Macroglobulinemia (WM)
14:50-15:10	WM1.2	S.S. Sahota, United Kingdom: Tracking the malignant cell of origin in Waldenström's Macroglobulinemia
15:10-15:30	WM1.3	R. Garcia-Sanz, Spain: Immunoglobulin gene rearrangements in WM
15:30-15:50	WM1.4	L.M. Pilarski, Canada: Inherited and acquired mutations in Waldenström's Macroglobulinemia (WM): WM and MM have a close genetic relationship not shared with B-CLL
15:50-16:10	WM1.5	R. Fonseca, USA: Genetics and Genomics of Waldenström Macroglobulinemia
16:10-16:30	WM1.6	E. Morra, Italy: IgM MGUS and Asymptomatic WM: Prognostic factors and evolution
16:30-16:50	WM1.7	P. Morel, France: International prognostic scoring system for Waldenström's Macroglobulinemia
17:00-18:00		Poster Session III

*Saturday, June 30, 2007**Hall Hippocrates*

08:00-10:00	WM2	Frontline treatment of WM Chair: M. Gertz, USA
08:00-08:20	WM2.1	R.A. Kyle, USA: Indications for treatment and the role of Alkylating agents in WM
08:20-08:40	WM2.2	V. LeBlond, France: Role of purine analogs in front-line treatment of Waldenström's Macroglobulinemia
08:40-09:00	WM2.3	D.M. Weber, USA: Rituximab alone or in combination in the frontline treatment of WM
09:00-09:20	WM2.4	M.A. Gertz, USA: Overview in salvage treatment in WM
09:20-09:40	WM2.5	A. Anagnostopoulos, Greece: The role of autologous transplantation in WM
09:40-10:00	WM2.6	S.P. Treon, USA: Novel agents in the treatment of Waldenström's Macroglobulinemia: Update of WMCTG Clinical Trials
10:00-10:30		Coffee Break

Hall Hippocrates

10:30-13:20	WM3	Novel treatment approaches, treatment of advanced disease Chair: V. LeBlond, France - A. Anagnostopoulos, Greece
10:30-10:50	WM3.1	I. Ghobrial, USA: Proteomic analysis in WM
10:50-11:05	WM3.2	N.C. Gutierrez, Spain: The gene expression signature of clonal cells from Waldenström's Macroglobulinemia: differences and commonalities with the normal cell counterpart and other related lymphoproliferative disorders
11:05-11:20	WM3.3	E. Hatjiharissi, USA: Gene expression profiling of Waldenström's Macroglobulinemia reveals genes that may be related to disease pathogenesis

Saturday, June 30, 2007 ■

Hall Hippocrates

- | | | |
|-------------|--------|--|
| 11:20-11:35 | WM3.4 | E. Hatjiharissi, USA: Novel splice variant transcript of Siva in Waldenström's Macroglobulinemia |
| 11:35-11:50 | WM3.5 | S. Adamia, USA: Aberrant post-transcriptional regulation of TNF family members and their adaptor molecules essential to B-cell growth and survival in Waldenström's Macroglobulinemia |
| 11:50-12:05 | WM3.6 | B.T. Ciccarelli, USA: The functional role of CD27-CD70 interactions in Waldenström's Macroglobulinemia |
| 12:05-12:20 | WM3.7 | A. Anagnostopoulos, Greece: Serum concentrations of angiogenic cytokines in Waldenström's Macroglobulinemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity |
| 12:20-12:35 | WM3.8 | J. Soumerai, USA: Use of the immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenström's Macroglobulinemia |
| 12:35-12:50 | WM3.9 | C. Kyriakou, United Kingdom: Allogeneic stem cell transplantation (ALLO-SCT) in Waldenström's Macroglobulinemia (WM). An analysis of 106 cases from the european bone marrow registry (EBMT) |
| 12:50-13:05 | WM3.10 | X. Leleu, USA: Increased incidence of disease transformation and development of MDS/AML in Waldenström's Macroglobulinemia (WM) patients treated with nucleoside analogues. |
| 13:05-13:20 | WM3.11 | A.D. Wechalekar, United Kingdom: Clinical Profile And Treatment Outcome In 103 Patients With AL Amyloidosis Associated With IgM Paraproteinemia |
| 13:20-14:30 | | Lunch Break |

Hall Hippocrates

14:30-16:30

Consensus on WM treatment

Chair: **S.P. Treon, USA** - **M.A. Dimopoulos, Greece**